105

Tofacitinib

105 Publications Verification

Cat. No.: HY-40354

CAS No.: 477600-75-2

Synonyms: Tasocitinib; CP-690550

Target:

JAK STAT NF-κB

Research Areas:

Neurological Disease Metabolic Disease Inflammation/Immunology

Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

105

Tofacitinib citrate

105 Publications Verification

Cat. No.: HY-40354A

CAS No.: 540737-29-9

Synonyms: Tasocitinib citrate; CP-690550 citrate

Target:

JAK STAT NF-κB

Research Areas:

Neurological Disease Metabolic Disease Inflammation/Immunology

Tofacitinib citrate (Tasocitinib citrate) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib citrate blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib citrate can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

78

Cilengitide

78 Cited Publications

Cat. No.: HY-16141

CAS No.: 188968-51-6

Synonyms: EMD 121974

Target:

Integrin TGF-β Receptor Apoptosis PD-1/PD-L1 STAT Akt mTOR

Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC₅₀ values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

78

Cilengitide TFA

78 Cited Publications

Cat. No.: HY-16143

CAS No.: 199807-35-7

Synonyms: EMD 121974 TFA

Target:

Integrin TGF-β Receptor Apoptosis PD-1/PD-L1 STAT Akt mTOR

Cilengitide TFA (EMD 121974 TFA) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC₅₀ values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide TFA inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide TFA inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide TFA can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

72

Exendin-4 acetate

72 Cited Publications

Cat. No.: HY-13443A

CAS No.: 914454-01-6

Purity: 99.91%

Synonyms: Exenatide acetate

Target:

GLP Receptor Apoptosis

Research Areas:

Cardiovascular Disease Metabolic Disease

Exendin-4 acetate (Exenatide acetate) is an orally active, blood-brain barrier-permeable glucagon-like peptide-1 receptor (GLP‑1 receptor) agonist that resists degradation mediated by dipeptidyl peptidase IV. Exendin-4 acetate mediates multiple glucose-regulating effects, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon production, increase in β-cell mass, delay of gastric emptying, reduction of food intake, improvement of peripheral insulin sensitivity, and restoration of normal islet structure. Exendin-4 acetate inhibits oxidative stress, alleviates inflammatory responses, and reduces neuronal apoptosis. Exendin-4 acetate reduces the aggregation level of mutant huntingtin, improves motor function, prolongs survival time, and regulates the expression levels of leptin and ghrelin. Exendin-4 acetate can be used in research related to type 2 diabetes, acute ischemic stroke, and Huntington's disease .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

72

Exendin-4

72 Cited Publications

Cat. No.: HY-13443

CAS No.: 141758-74-9

Purity: 99.95%

Synonyms: Exenatide

Target:

GLP Receptor Apoptosis

Research Areas:

Cardiovascular Disease Metabolic Disease

Exendin‑4 (Exenatide) is an orally active, blood-brain barrier-permeable glucagon-like peptide-1 receptor (GLP‑1 receptor) agonist that resists degradation mediated by dipeptidyl peptidase IV. Exendin‑4 mediates multiple glucose-regulating effects, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon production, increase in β-cell mass, delay of gastric emptying, reduction of food intake, improvement of peripheral insulin sensitivity, and restoration of normal islet structure. Exendin‑4 inhibits oxidative stress, alleviates inflammatory responses, and reduces neuronal apoptosis. Exendin‑4 reduces the aggregation level of mutant huntingtin, improves motor function, prolongs survival time, and regulates the expression levels of leptin and ghrelin. Exendin‑4 can be used in research related to type 2 diabetes, acute ischemic stroke, and Huntington's disease .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

20

Rolipram

20 Cited Publications

Cat. No.: HY-16900

CAS No.: 61413-54-5

Synonyms: (R,S)-Rolipram; (±)-Rolipram; ZK 62711

Target:

Bacterial HIV Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β

Research Areas:

Infection Neurological Disease Cancer

Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

12

ML334

12 Cited Publications

Cat. No.: HY-110258

CAS No.: 1432500-66-7

Purity: ≥99.0%

Synonyms: LH601A

Target:

Quinone Reductase Keap1-Nrf2

Research Areas:

Cancer

ML334 is a potent, cell permeable activator of NRF2 by inhibition of Keap1-NRF2 protein-protein interaction. ML334 binds to Keap1 Kelch domain with a K_d of 1 μM. ML334 stimulates NRF2 expression and nuclear translocation and induces antioxidant response elements (ARE) activity .

Compare

loading...